Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant.: The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482))

[No Value] Garderet; Francesco Onida

doi:10.1200/JCO.2012.46.1848

Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant. The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482))

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	3429
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	30
Issue number	27
DOIs	https://doi.org/10.1200/JCO.2012.46.1848
Publication status	Published - Sep 20 2012

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1200/JCO.2012.46.1848

Cite this

Garderet, N. V., & Onida, F. (2012). Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant. The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482)). Journal of Clinical Oncology, 30(27), 3429. https://doi.org/10.1200/JCO.2012.46.1848

Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant. The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482)). / Garderet, [No Value]; Onida, Francesco.

In: Journal of Clinical Oncology, Vol. 30, No. 27, 20.09.2012, p. 3429.

Research output: Contribution to journal › Article › peer-review

Garderet, NV & Onida, F 2012, 'Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant. The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482))', Journal of Clinical Oncology, vol. 30, no. 27, pp. 3429. https://doi.org/10.1200/JCO.2012.46.1848

Garderet NV, Onida F. Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant. The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482)). Journal of Clinical Oncology. 2012 Sep 20;30(27):3429. https://doi.org/10.1200/JCO.2012.46.1848

Garderet, [No Value] ; Onida, Francesco. / Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant. The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482)). In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 27. pp. 3429.

@article{296ba04c05894e4fbffb140ca45fe348,

title = "Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant.: The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482))",

author = "Garderet, {[No Value]} and Francesco Onida",

year = "2012",

month = sep,

day = "20",

doi = "10.1200/JCO.2012.46.1848",

language = "English",

volume = "30",

pages = "3429",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "27",

}

TY - JOUR

T1 - Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant.

T2 - The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482))

AU - Garderet, [No Value]

AU - Onida, Francesco

PY - 2012/9/20

Y1 - 2012/9/20

UR - http://www.scopus.com/inward/record.url?scp=84866751744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866751744&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.46.1848

DO - 10.1200/JCO.2012.46.1848

M3 - Article

AN - SCOPUS:84866751744

VL - 30

SP - 3429

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 27

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this